SpyGlass Pharma is a publicly traded pharmaceutical company (NASDAQ: SGP) focused on developing innovative long-term ophthalmic drug delivery technologies for patients with chronic eye diseases. The company is advancing the SpyGlass BIM-IOL, a sustained therapy treatment designed to be delivered through cataract surgery to improve patient outcomes while minimizing treatment burden. Built by a collaborative team with deep expertise in ophthalmology, drug delivery, pharmaceuticals, and medical devices, SpyGlass Pharma is currently advancing its lead program through Phase 3 clinical development. The company is guided by the principle 'We create for patients,' which shapes their product development, team building, and organizational culture.
Beta · Sourced from candidate reports
Be the first to share your experience with SpyGlass Pharma.
Your reply helps other candidates know what to expect.
